201 related articles for article (PubMed ID: 24926732)
1. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation.
Nelson WW; Song X; Coleman CI; Thomson E; Smith DM; Damaraju CV; Schein JR
Curr Med Res Opin; 2014 Dec; 30(12):2461-9. PubMed ID: 24926732
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation.
Spivey CA; Qiao Y; Liu X; Mardekian J; Parker RB; Phatak H; Claflin AB; Kachroo S; Abdulsattar Y; Chakrabarti A; Wang J
J Manag Care Spec Pharm; 2015 Jul; 21(7):596-606. PubMed ID: 26108384
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban's Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis.
Coleman CI; Kreutz R; Sood N; Bunz TJ; Meinecke AK; Eriksson D; Baker WL
Clin Appl Thromb Hemost; 2019; 25():1076029619868535. PubMed ID: 31392894
[TBL] [Abstract][Full Text] [Related]
4. Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF.
Ungar L; Rodriguez F; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Nessel CC; Singer DE; Patel MR; Piccini JP; Mahaffey KW
Cardiol Ther; 2019 Dec; 8(2):283-295. PubMed ID: 31376090
[TBL] [Abstract][Full Text] [Related]
5. Thromboembolic and neurologic sequelae of discontinuation of an antihyperlipidemic drug during ongoing warfarin therapy.
Leonard CE; Brensinger CM; Bilker WB; Kimmel SE; Whitaker HJ; Hennessy S
Sci Rep; 2017 Dec; 7(1):18037. PubMed ID: 29269848
[TBL] [Abstract][Full Text] [Related]
6. Is Lighter Intensity of Warfarin Therapy Enough for Korean Patients with Non-Valvular Atrial Fibrillation?
Lee SR
Korean Circ J; 2020 Feb; 50(2):176-178. PubMed ID: 31845561
[No Abstract] [Full Text] [Related]
7. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry.
Beyer-Westendorf J; Förster K; Ebertz F; Gelbricht V; Schreier T; Göbelt M; Michalski F; Endig H; Sahin K; Tittl L; Weiss N
Europace; 2015 Apr; 17(4):530-8. PubMed ID: 25694537
[TBL] [Abstract][Full Text] [Related]
8. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation.
Nelson WW; Song X; Thomson E; Smith DM; Coleman CI; Damaraju CV; Schein JR
Curr Med Res Opin; 2015; 31(10):1831-40. PubMed ID: 26211816
[TBL] [Abstract][Full Text] [Related]
9. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban.
Tamayo S; Frank Peacock W; Patel M; Sicignano N; Hopf KP; Fields LE; Sarich T; Wu S; Yannicelli D; Yuan Z
Clin Cardiol; 2015 Feb; 38(2):63-8. PubMed ID: 25588595
[TBL] [Abstract][Full Text] [Related]
10. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
Martinez C; Katholing A; Wallenhorst C; Freedman SB
Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N
Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533
[TBL] [Abstract][Full Text] [Related]
12. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.
Lauffenburger JC; Farley JF; Gehi AK; Rhoney DH; Brookhart MA; Fang G
J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25862791
[TBL] [Abstract][Full Text] [Related]
14. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.
Forslund T; Wettermark B; Hjemdahl P
Eur J Clin Pharmacol; 2016 Mar; 72(3):329-38. PubMed ID: 26613954
[TBL] [Abstract][Full Text] [Related]
15. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications.
Crivera C; Nelson WW; Bookhart B; Martin S; Germain G; Laliberté F; Schein J; Lefebvre P
Curr Med Res Opin; 2015; 31(10):1889-95. PubMed ID: 26211815
[TBL] [Abstract][Full Text] [Related]
16. Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.
Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
Hosp Pract (1995); 2014 Aug; 42(3):17-25. PubMed ID: 25255403
[TBL] [Abstract][Full Text] [Related]
17. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Kuhls S; van Eickels M; Turpie AG;
Eur Heart J; 2016 Apr; 37(14):1145-53. PubMed ID: 26330425
[TBL] [Abstract][Full Text] [Related]
18. Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
Chatterjee S; Sardar P; Giri JS; Ghosh J; Mukherjee D
Mayo Clin Proc; 2014 Jul; 89(7):896-907. PubMed ID: 24996233
[TBL] [Abstract][Full Text] [Related]
19. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Clin Ther; 2015 Mar; 37(3):554-62. PubMed ID: 25749196
[TBL] [Abstract][Full Text] [Related]
20. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
Beyer-Westendorf J; Ehlken B; Evers T
Europace; 2016 Aug; 18(8):1150-7. PubMed ID: 26830891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
